Bioanalysis of Drug Conjugate Modalities
Global bioanalytical support for conjugates: ADC, PDC, AOC, and more.
Expert bioanalysis for
complex drug conjugates
Technology-aligned bioanalytical solutions for all types of drug conjugates and their formulations.
Our Expertise
- Deep scientific understanding of formulated
drug conjugate modalities - Development, validation and analysis for conjugates:
- Ab drug (ADC)
- Ab oligo (AOC)
- Peptide or polymer-drug (PDC)
- Lipid nanoparticle (LNP/LDC)
- Aptamers, and more
- Understanding modification and structure effects on bioanalysis and overcoming assay challenges
- Ultra-sensitive methods for high potency
small molecule payloads - Strong understanding of LNP/LDC formulations: multiple assays for carriers and active drug substance, free vs encapsulated drug quantitaion, sample handling and stabilization
- PK/TK, PD, ADA for all stages of drug development
Your partner
- Consultative approach with personalized support and dedicated teams and instrumentation for your studies
- Fit-for-purpose assay development depending on stage of development and compliance requirements
- Instrument platform agnostic ensuring study needs are met:
LC-MS/MS, LC-HRAM, LC-FL, MSD, PCR, and LBA - Collaboration to understand modality and formulation, study requirements and endpoints
- Trusted globally by leading biopharma companies
- Extensive regulatory compliance experience with FDA, EMA, ICH (M10), NMPA and NATA
Bioanalysis Drug Conjugates
-
Antibody-drug conjugate (ADC)
A targeted therapeutic combining a monoclonal antibody with a cytotoxic drug, enabling precise delivery to specific cells such as cancer cells. -
Antibody-oligonucleotide conjugate (AOC)
A fusion of an antibody and an oligonucleotide that directs nucleic acid-based therapies to specific tissues or cells.
-
Peptide or polymer-drug conjugate (PDC)
A drug linked to a peptide or polymer to enhance stability, solubility, or targeted delivery of therapeutic agents. -
Lipid nanoparticle (LNP/LDC)
Anano-scale delivery system using lipid-based carriers to transport nucleic acids or drugs across cell membranes, commonly used in mRNA therapies. - Aptamers
Short, single-stranded DNA or RNA molecules that fold into unique shapes to bind specific targets with high affinity, offering a synthetic alternative to antibodies for therapeutic or diagnostic use.
